Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?

Authors

  • Barbara Picconi PhD,

    1. Fondazione Santa Lucia, IRCCS, Rome, Italy
    Search for more papers by this author
  • Paolo Calabresi MD

    Corresponding author
    1. Fondazione Santa Lucia, IRCCS, Rome, Italy
    2. Clinica Neurologica, Università degli studi di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
    • Correspondence to: Prof. Paolo Calabresi, MD, Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, 06156 Perugia, Italy; paolo.calabresi@unipg.it

    Search for more papers by this author

  • Funding agencies: This work was supported by Progetto di Ricerca di Interesse Nazionale (PRIN) 2011 (to P.C.) and Progetto del Ministero della Salute, Giovani Ricercatori (GR-2008-1142336; to B.P.).

  • Relevant conflicts of interest/financial disclosures: Nothing to report.

  • Full financial disclosures and author roles may be found in the online version of this article.

Abstract

Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results. © 2014 International Parkinson and Movement Disorder Society

Ancillary